Nexalin Technology, Inc. (NXL)
| Market Cap | 38.43M |
| Revenue (ttm) | 152,570 |
| Net Income (ttm) | -5.94M |
| Shares Out | 6.41M |
| EPS (ttm) | -0.93 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | n/a |
| Previous Close | n/a |
| Day's Range | n/a |
| 52-Week Range | n/a |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | n/a |
About NXL
Nexalin Technology designs and develops innovative neurostimulation products to uniquely and effectively help combat the ongoing global mental health epidemic. We have developed an easy-to-administer medical device — referred to as Gen-1 – that utilizes bioelectronic medical technology to treat anxiety and insomnia, without the need for drugs or psychotherapy. This device emits our original waveform at 4 milliamps during treatment and is classified by the FDA as a Class II device. While this device had been cleared by the FDA to treat anxie...
Financial Performance
In 2020, NXL's revenue was $242,914, an increase of 17.13% compared to the previous year's $207,383. Losses were -$3.40 million, -32.22% less than in 2019.
Financial StatementsNews
Nexalin Technology, Inc. IPO Registration Document (S-1)
Nexalin Technology, Inc. has filed to go public with an IPO on the NASDAQ.